ERBB2 and breast carcinoma: Trastuzumab (Herceptin), a monoclonal antibody against the HER2 receptor, was the first major breakthrough in the treatment of HER2-positive breast cancer (Oliveira, Braga, Passos-Coelho, Fonseca, & Oliveira, 2011).